Loading…
JAMP LEVOFLOXACIN is a brand name for Levofloxacin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ........................................................................................3 CONTRAINDICATIONS ..........................................................................................................5 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
, and CLINICAL TRIALS). Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae or Streptococcus pneumoniae.
Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended. JAMP Levofloxacin is not indicated for acute bronchitis.
JAMP Levofloxacin should not be prescribed to patients with acute bacterial exacerbations of simple/uncomplicated chronic obstructive pulmonary disease (ie. patients who have chronic obstructive pulmonary disease without underlying risk factors) 2 Skin and Skin Structure Uncomplicated skin and skin structure infections (mild to moderate) due to Staphylococcus aureus or Streptococcus pyogenes.
Complicated skin and skin structure infections (mild to moderate), excluding burns, due to Enterococcus faecalis, methicillin-sensitive Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis, or Streptococcus agalactiae. Urinary Tract Complicated urinary tract infections (mild to moderate) due to Enterococcus (Streptococcus) faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa (see DOSAGE AND ADMINISTRATION and CLINICAL TRIALS).
Uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae or Staphylococcus saprophyticus. Acute pyelonephritis (mild to moderate) caused by Escherichia coli (see DOSAGE AND ADMINISTRATION and CLINICAL TRIALS).
Chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing the infection, and to determine their susceptibility to levofloxacin.
Therapy with JAMP Levofloxacin may be initiated before the results of these tests are known; once results become available, appropriate therapy should be continued. In cases of uncomplicated acute bacterial cystitis, limit the use of JAMP Levofloxacin to circumstances where no other treatment options are available.
A urine culture should be obtained prior to treatment to ensure levofloxacin susceptibility. 2 Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Levofloxacin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
O’Donnell et al. Can Respir J 2008; 15 (Suppl A): 1A-8A. JAMP Levofloxacin Page 5 of 68 As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with JAMP Levofloxacin.
Culture and susceptibility testing performed periodically during therapy, will reveal not only the therapeutic effect of the antimicrobial agent, but also the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of JAMP Levofloxacin and other antibacterial drugs, JAMP Levofloxacin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Geriatrics (≥65 years of age):
Drug absorption appears to be unaffected by age. Dose adjustment based on age alone is not necessary (see WARNINGS AND PRECAUTIONS, Special Populations and ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions).
Pediatric Use (<18 years of age):
Safety and effectiveness in children under 18 years of age have not been established (see WARNINGS AND PRECAUTIONS, Special Populations). CONTRAINDICATIONS JAMP Levofloxacin is contraindicated in persons with a history of hypersensitivity to levofloxacin, quinolone antimicrobial agents, or to any components of this product.
For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph. JAMP Levofloxacin is also contraindicated in persons with a history of tendinitis or tendon rupture associated with the use of any member of the quinolone group of antimicrobial agents.
WARNINGS AND PRECAUTIONS Serious Warnings and Precautions Levofloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients (see WARNINGS AND PRECAUTIONS, Cardiovascular). Serious hypersensitivity and/or anaphylactic reactions have been reported in patients receiving quinolone therapy, including levofloxacin (see WARNINGS AND PRECAUTIONS, Immune).
Seizures may occur with quinolone therapy. JAMP Levofloxacin should be used with caution in patients with known or suspected CNS disorders which may predispose to seizures or lower the seizure threshold (see WARNINGS AND PRECAUTIONS, Neurologic).
JAMP Levofloxacin Page 6 of 68 General The administration of levofloxacin increased the incidence and severity of osteochondrosis in immature rats and dogs. Other quinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species.
Consequently, levofloxacin should not be used in pre-pubertal patients (see TOXICOLOGY). Although levofloxacin is soluble, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine.
Crystalluria has been observed rarely in patients receiving other quinolones, when associated with high doses and an alkaline urine. Although crystalluria was not observed in clinical trials with levofloxacin, patients are encouraged to remain adequately hydrated.
As with any antimicrobial drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is […]